Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

See which leaders are on the move across the pharma, biotech and medical marketing industries.

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the ...

“Men with metastatic castration-resistant prostate cancer are often faced with a poor prognosis and limited treatment options, and Talzenna in combination with Xtandi has redefined the ...

Pfizer has earned a consensus rating of “Moderate Buy” from fifteen analysts, with only one calling it a “sell.” The average analyst price target is $29.17, despite recent coverage showing a cautious ...

The Food and Drug Administration has updated its warning labels for the Pfizer and Moderna COVID-19 vaccines, expanding information about a rare but potential heart-related side effect. The ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.